In a recent Select Science Editorial Article, Dr. Harald Messer, Gene Therapies Senior Scientist at Novartis, talks about the key considerations and challenges associated with developing biologically relevant cell-based assays that reflect mechanisms of action (MoA) and drug potency that represent the functionality and safety of gene therapy products.
The article also deals with the need for robust, customized assays in gene therapy, key considerations for potency testing, and much more.